Drug intelligence / Profile preview

lexatumumab

Development stage: Phase 1
Lead developer: GSK
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Lexatumumab is a fully human monoclonal antibody that targets the tumor necrosis factor-related apoptosis-inducing ligand receptor 2 (TRAIL-R2, also known as death receptor 5 or DR5). It was developed as an investigational anti-cancer agent designed to induce apoptosis in cancer cells by activating the extrinsic apoptotic pathway through binding and agonism of TRAIL-R2. Lexatumumab was primarily investigated for the treatment of various solid tumors and hematological malignancies. The drug was originally developed by Human Genome Sciences.

Targets

TNFRSF10B (DR5)

Beyond the preview

Go deeper on lexatumumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on lexatumumab.

Explore the full profile